Association of NOTCH1 mutations in pediatric T-cell acute lymphoblastic leukemia with treatment relapse and expression of genes relevant to chemotherapy response
Amanda Larson Gedman,Yubin Ge,Katherine M. LaFiura,Meenakshi Devidas,Stephen B. Linda,Jeffrey W. Taub,Larry H. Matherly
IF: 11.2
2007-01-01
Cancer Research
Abstract:1796 Recent reports have identified high frequency gain-of-function mutations in the heterodimeric NOTCH1 receptor in T-cell acute lymphoblastic leukemia (T-ALL). Although this suggests an important role for NOTCH1 signaling in the molecular pathogenesis of this disease, the prognostic significance of these findings remains controversial. In this report, we explore the association between NOTCH1 mutations in T-ALL, treatment failure, and expression of individual genes relevant to T-ALL chemotherapy and encoding metabolizing enzymes, transporters, drug targets, or apoptosis proteins. Lymphoblast RNAs from a case-control population of 40 T-ALL patients [21 relapsed within 4 y (cases), 19 did not relapse (controls)] were analyzed by RT-PCR and DNA sequencing to identify mutations in NOTCH1 heterodimerization (HD) and PEST domains, reported to be mutation “hot spots”. Transcript levels were measured by real-time RT-PCR for (a) ABCG2, (b) ABCC1, (c) ABCC2, (d) ABCC3, (e) ABCC4, (f) ABCC5, (g) asparagine synthetase, (h) BCL2, (i) BCL-XL, (j) dihydrofolate reductase (DHFR), (k) folylpolyglutamate synthetase, (l) glucocorticoid receptor, (m) human reduced folate carrier, (n) hypoxanthine phosphoribosyl transferase (HPRT), (o) MDR1, (p) topoisomerase 2 α (TOP2A), and (q) topoisomerase 2 β (TOP2B). NOTCH1 mutations were detected in 14 patients (6 HD, 3 PEST, and 5 HD plus PEST together) including point mutations, deletions and insertions. Wild type NOTCH1 sequence was detected in 26 patients. There was no difference in the frequency of relapse between groups of patients (8/14) who harbored NOTCH1 mutations and those who did not (13/26). However, for the 23 children treated with a single (POG8704) protocol, NOTCH1 mutations were associated with a reduced incidence of relapse (3/13 cases and 6/10 controls harbored NOTCH1 mutations). Mutated NOTCH1 was associated with 2-7-fold decreased transcript levels for ABCG2, ABCC1, ABCC4, DHFR, BCL-XL, HPRT, TOP2A, and TOP2B. Our results imply that the presence of NOTCH1 mutations confers a good prognosis in pediatric T-ALL, however, this appears to be protocol dependent. NOTCH1 mutations result in decreased expression of genes that impact chemotherapy sensitivity, thereby influencing the effectiveness of therapy, depending on the drug combinations employed.